Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, shared a post on LinkedIn about a recent paper he co-authored with colleagues published in Cancer Treatment Reviews:
“Do ADCs work when used in sequence?
We systematically reviewed 23 studies (including nearly 3000 patients), finding that: it depends!
Relevant cross-resistance is seen if two TOPO1 ADCs are sequenced (irrespective of target). PFS declined from 5-8 months with ADC1 to only 2-3 months with ADC2.
Less cross-resistance is seen if switching payload class (even if the target is the same). Key example: T-DXd and T-DM1 (each works quite well after the other).
Free access to the article for ESMO – European Society for Medical Oncology members.”
Title: Sequencing antibody-drug conjugates in metastatic breast cancer: A systematic review
Authors: Luiz F. Costa de Almeida, Luís Felipe Leite, Anelise Poluboiarinov Cappellaro, Lucas Diniz da Conceição, Mariana Macambira Noronha, Jessé Lopes da Silva, Andreia Cristina de Melo, Felipe Batalini, Paolo Tarantino
Read the Full Article in Cancer Treatment Reviews.
More posts featuring Paolo Tarantino on OncoDaily.